Lake Street Capital Lowers Cardlytics (NASDAQ:CDLX) Price Target to $3.00

Cardlytics (NASDAQ:CDLX) had its price target dropped by stock analysts at Lake Street Capital from $5.00 to $3.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Lake Street Capital’s target price would indicate a potential upside of 21.46% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday. Evercore ISI decreased their price objective on Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Cardlytics presently has a consensus rating of “Hold” and a consensus price target of $6.42.

Cardlytics Stock Performance

Shares of CDLX stock opened at $2.47 on Thursday. The firm has a market capitalization of $125.53 million, a price-to-earnings ratio of -0.40 and a beta of 1.62. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The business has a fifty day moving average of $3.02 and a 200 day moving average of $3.50. Cardlytics has a 1 year low of $1.77 and a 1 year high of $20.52.

Insider Buying and Selling

In related news, CEO Amit Gupta sold 46,857 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $159,313.80. Following the completion of the transaction, the chief executive officer now owns 418,637 shares of the company’s stock, valued at approximately $1,423,365.80. This represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alexis Desieno sold 24,778 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the completion of the transaction, the chief financial officer now directly owns 140,948 shares of the company’s stock, valued at $479,223.20. The trade was a 14.95 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 111,454 shares of company stock valued at $391,864. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cardlytics

A number of large investors have recently bought and sold shares of the business. Tallon Kerry Patrick purchased a new stake in Cardlytics during the 4th quarter worth approximately $37,000. Atom Investors LP purchased a new stake in Cardlytics during the 3rd quarter worth approximately $33,000. ProShare Advisors LLC purchased a new stake in Cardlytics during the 4th quarter worth approximately $43,000. Intech Investment Management LLC purchased a new stake in Cardlytics during the 3rd quarter worth approximately $47,000. Finally, Virtu Financial LLC purchased a new stake in Cardlytics during the 4th quarter worth approximately $62,000. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.